Nature Communications, Published online: 30 June 2026; doi:10.1038/s41467-026-75098-2 The study shows that Ip6k2 partners with Runx2 to drive osteoclast activity. Targeting Ip6k2 selectively reduces bone resorption, increases bone mass, and protects against osteoporosis without affecting bone formation.